Pandion Therapeutics
Cambridge
About Pandion Therapeutics
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $138.0M
- Funding stage: M&A
- Last round: Series B (Apr 2020)
- Ticker: nasdaq:PAND
- Website: pandiontx.com
- Phone: (617) 393-5925
Industries & Categories
Biotechnology, Health Care, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/pandion-therapeutics-106546 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.